Overview

Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia

Status:
Completed
Trial end date:
2020-04-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects a new drug, buparlisib, has on chronic lymphocytic leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborator:
Novartis